The DOI matches its Crossref record.
Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
Abstract
BACKGROUND: Atomoxetine is a nonstimulant drug being studied for the treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a highly specific inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or other neurotransmitter transporters or receptors. Results of 2 proof-of-concept studies are reported that tested the hypothesis that a selective inhibitor of presynaptic norepinephrine uptake would be effective for the treatment of ADHD in school-aged children. METHOD: Two identical 12-week, stratified, randomized, double-blind, placebo-controlled trials were conducted in children who met DSM-IV criteria for ADHD. The primary efficacy outcome measure was the mean change from baseline to endpoint in the Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD RS) total score. Secondary efficacy measures included the Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) and the Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S). RESULTS: A total of 291 patients were randomized in the 2 trials combined (Study 1, N = 147; Study 2, N = 144). Stimulant-naive patients were randomized to atomoxetine, placebo, or methylphenidate. Patients with prior stimulant exposure were randomized to atomoxetine or placebo. Atomoxetine significantly reduced ADHD RS total scores compared with placebo in each study (p <.001). Changes in the CGI-ADHD-S (Study 1: p =.003; Study 2: p =.001) and CPRS-ADHD Index (Study 1: p =.023; Study 2: p <.001) also showed atomoxetine to be statistically significantly superior to placebo in reducing ADHD symptoms. Atomoxetine was found to be well tolerated in this population of pediatric patients. CONCLUSION: Two studies of atomoxetine early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD. In addition, atomoxetine was found to be well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine randomized trials comparing methylphenidate and atomoxetine, with a total of 2762 participants were included.”
In the citing paper
“The outcome in three of these trials favoured atomoxetine suggesting that higher doses of atomoxetine administered twice daily may be more effective.”
In the citing paper
“When data on standard deviations were missing, study authors were contacted to provide missing data [18] or it was calculated using the standard error of subgroups or confidence intervals [19-21].”
Citations
Cited by
Sorted by citations
Items 301–335 of 335
Hazell, P. (2004) · Australasian Psychiatry · doi:10.1111/j.1440-1665.2004.02129.x · Cited by 1
Attention-Deficit/Hyperactivity Disorder
Mandelbaum, D. E., & Silver, W. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00075-5 · Cited by 1
Bioethical Issues in Medicinal Chemistry and Drug Treatment
Wolpe, P., Sahl, M., & Howard, J. R. (2007) · Comprehensive Medicinal Chemistry II · doi:10.1016/b0-08-045044-x/00025-0 · Cited by 2
Taracena, M. T. D. L., & Rada, F. M. (2007) · Psiquiatría Biológica · doi:10.1016/s1134-5934(07)73255-4 · Cited by 1
Turan, S., & Akay, A. P. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1637393 · Cited by 1
An IT-based teaching model for a new generation of students
Édgar Serna, M., & Alexei Serna, A. (2021) · Journal of Educational Change · doi:10.1007/s10833-020-09390-3 · Cited by 1
Perspectives in psychopharmacology: spotlight on atomoxetine.
Virani, A. S. (2005) · PubMed Central · Cited by 1
Banerjee, S., & Ayyash, H. F. (2008) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2008.142356 · Cited by 1
Gaillez, C., Sorbara, F., & Perrin, E. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)92063-1 · Cited by 1
InforMatrix for attention deficit hyperactivity disorder
Janknegt, R., Faber, A., Pereira, R. R., & Kalverdijk, L. J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902765769 · Cited by 1
“Atomoxetine 15 > 1000 6 > 100 million [13-27,35]”
MethodNeuropharmacology of Attention‐Deficit/Hyperactivity Disorder
Glaser, P. E. A., Castellanos, F. X., & Margulies, D. S. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn056
Papakostas, G. I., Petersen, T., Perlis, R. H., et al. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203226.79364.5e
New Medication Strategies for Comorbid Substance Use and Bipolar Affective Disorders
Kosten, T. R., & Kosten, T. A. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc262
Updates on combination pharmacotherapy for adult ADHD
Adler, L. A., Shaw, D. M., Reingold, L. S., Morrill, M. I., & Wilens, T. E. (2009) · Current Attention Disorders Reports · doi:10.1007/s12618-009-0015-2
&NA; (2003) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200319100-00002
Feifel, D. (2007) · PubMed Central
C.3 Aufmerksamkeits-Defizit-Hyperaktivitäts-Störungen
Walitza, S., & Warnke, A. (2004)
Signorovitch, J., Sikirica, V., Erder, M. H., Xie, J., Lü, M., Hodgkins, P., Betts, K. A., & Wu, E. Q. (2012)
ATOMOKSETÝN: ÇOCUK VE ERGENLERDEKÝ ETKÝNLÝÐÝ VE YAN ETKÝLERÝ
Öç, Ö. Y., Karakaya, İ., & Memýk, N. Ç. (2007)
Evidence-based pharmacotherapy of attention deficit hyperactivity disorder
Vaughan, B. S., March, J. S., & Kratochvil, C. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.002
Self-citationChildhood Neuropsychiatric Risk
Elia, J., Borgmann‐Winter, K. E., & Grice, D. E. (2010) · Issues in clinical child psychology · doi:10.1007/978-1-4419-5800-6_16
“, 1999), and the spontaneously hyperactive rat model where reduced α2 adrenoceptor-mediated inhibition of NE release mediates hyperactivity (Russell, Allie, & Wiggins, 2000) have pointed to a noradrenergic focus that has been bolstered by efficacy of selective norepinephrine transporter (NET) inhibitor, atomoxetine, s…”
BackgroundGökten, E. S. (2018) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.408139
Current Awareness in Human Psychopharmacology
(2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.460
Yates, T. (2004) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.9.6.1.55492
(2003) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.8.3.8.23075
Erder, M. H., Xie, J., Signorovitch, J., et al. (2012) · Applied Health Economics and Health Policy · doi:10.2165/11641870-000000000-00000
Knouse, L. E. (2004) · The ADHD Report · doi:10.1521/adhd.12.2.12.30978
Walitza, S., Smigielski, L., & Gerlach, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_8 · Cited by 2
Zhang, Y., Miao, Y.-Y., Wang, F., Li, X., Wang, J., Wang, Z., Ren, Q.-S., Wang, Y.-L., Yuan, F.-J., Zhou, Y.-J., et al. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i10.110404
Remission versus response as the goal of therapy in ADHD: A new standard for the field?
Steele, M., Jensen, P. S., & Quinn, D. M. P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.006 · Cited by 174
Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99
Metadata
- Authors
- Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z.
- Affiliations
- Massachusetts General Hospital (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-12-15
- Volume
- 63
- Issue
- 12
- Pages
- 1140-1147
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2016483680
- Cited by
- 333
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 17 · 2013: 12 · 2012: 13
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, children, non-stimulant medication, norepinephrine transporter inhibitor, ADHD symptom reduction, methylphenidate, tolerability, ADHD Rating Scale
- MeSH terms
- Atomoxetine Hydrochloride, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Double-Blind Method, Female, Humans, Male, Propylamines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
